Concepedia

Klaus Podar

KP

Statistics

Publications

112

Citations

15.5K

H-Index

68

Active since

2000

Affiliations

Dana-Farber Cancer Institute(Current)

Harvard University

Heidelberg University

National Center for Tumor Diseases

Karl Landsteiner University of Health Sciences

Klaus Podar is an author at Dana-Farber Cancer Institute specializing in multiple myeloma, oncology, and medicine.

Publications per year

2000–2024

112

Publications

112

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

Faith E. Davies, Noopur Raje, Teru Hideshima et al. · Blood · 2001 · 905 citations

Medicine, Immunology, Oncology +12

A novel orally active proteasome inhibitor induces apoptosis in multiple myeloma cells with mechanisms distinct from Bortezomib

Dharminder Chauhan, Laurence Catley, Guilan Li et al. · Cancer Cell · 2005 · 698 citations · Full text

Medicine, Oncology, Pharmacology +14

Oral Selinexor–Dexamethasone for Triple-Class Refractory Multiple Myeloma

Ajai Chari, Dan T. Vogl, Maria Gavriatopoulou et al. · New England Journal of Medicine · 2019 · 673 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Molecular mechanisms mediating antimyeloma activity of proteasome inhibitor PS-341

Teru Hideshima, Constantine S. Mitsiades, Masaharu Akiyama et al. · Blood · 2003 · 569 citations · Full text

Medicine, Oncology, Pharmacology +13

Adherence of multiple myeloma cells to bone marrow stromal cells upregulates vascular endothelial growth factor secretion: therapeutic applications

D. Gupta, SP Treon, Yoshihito Shima et al. · Leukemia · 2001 · 555 citations

Medicine, Cancer Biology, Cell Biology +15

1–5 of 112